Filtered By:
Cancer: Cancer
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 431 results found since Jan 2013.
Efficacy and safety of a dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study
CONCLUSIONS: The dexamethasone-based mouthwash safely reduced stomatitis incidence and severity in patients receiving chemotherapy for early breast cancer. Phase 3 clinical trials are warranted for validating our results.PMID:37689451 | DOI:10.1016/j.jebdp.2023.101896
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Sayaka Kuba Shigeto Maeda Kenichiro Shibata Sakiko Soutome Kosho Yamanouchi Megumi Matsumoto Aya Tanaka Michi Morita Toshiko Hatachi Ryota Otsubo Hiroshi Yano Yumiko Kawashita Shuntaro Sato Hideki Taniguchi Kengo Kanetaka Masahiro Umeda Takeshi Nagayasu S Source Type: research
Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma
CONCLUSIONS: This semi-automated analysis was in high agreement with standard approaches for detecting response to MM therapy. This proof-of-concept study suggests that larger studies should be conducted to confirm how FDG PET analysis may aid early response detection in MM.PMID:37657154 | DOI:10.1016/j.tranon.2023.101767
Source: Translational Oncology - September 1, 2023 Category: Cancer & Oncology Authors: Tyler J Wellman Sarah R Mudd Kelly N Godby Dustin W Wooten Jeremy A Ross Orlando F Bueno Danielle Wanik Chaitanya R Divgi Robert A Comley Luciano J Costa Jacob Y Hesterman Source Type: research
Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance
Eur J Pharmacol. 2023 Aug 22:175991. doi: 10.1016/j.ejphar.2023.175991. Online ahead of print.ABSTRACTThe use of repurposing drugs that may have neoplastic and anticancer effects increases the efficiency and decrease resistance to chemotherapy drugs through a biochemical and mechanical transduction mechanisms through modulation of fibroblast/fibrosis remodeling in tumor microenvironment (TME). Interestingly, fibroblast/fibrosis remodeling plays a vital role in mediating cancer metastasis and drug resistance after immune chemotherapy. The most essential hypothesis for induction of chemo-immunotherapy resistance is via activ...
Source: European Journal of Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Authors: Mahboubeh Tajaldini Amirhoushang Poorkhani Taghi Amiriani Amirhossein Amiriani Hossein Javid Parham Aref Farahnazsadat Ahmadi Somayeh Sadani Vahid Khori Source Type: research
Jianpi Decoction Combined with Medroxyprogesterone Acetate Alleviates Cancer Cachexia and Prevents Muscle Atrophy by Directly Inhibiting E3 Ubiquitin Ligase
CONCLUSIONS: Administration of JP combined with MPA restores tumor-induced cachexia conditions. In addition, the profound effect of JP combined with MPA on tumor-induced cachexia may be due to its inhibition of muscle proteolysis (E3 ubiquitinase system).PMID:37612478 | DOI:10.1007/s11655-023-3702-4
Source: Cancer Control - August 23, 2023 Category: Cancer & Oncology Authors: Qi Li Zhao-di Kong Huan Wang Hong-Hui Gu Zhong Chen Shi-Guang Li Yi-Qi Chen Yu Cai Zhen-Jiang Yang Source Type: research
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica. 2023 Aug 24. doi: 10.3324/haematol.2022.282624. Online ahead of print.ABSTRACTTo improve patient outcomes in the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient prognosis becomes worse after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) r...
Source: Cancer Control - August 23, 2023 Category: Cancer & Oncology Authors: Paul G Richardson Brian G Durie Laura Rosi ñol Maria-Victoria Mateos Angela Dispenzieri Philippe Moreau Shaji Kumar Noopur Raje Nikhil Munshi Jacob P Laubach Peter O'Gorman Elizabeth O'Donnell Peter Voorhees Thierry Facon Joan Blad é Sagar Lonial Aurore Source Type: research
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
CONCLUSION: Atezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile.PMID:37603816 | DOI:10.1200/JCO.22.02561
Source: Clinical Lung Cancer - August 21, 2023 Category: Cancer & Oncology Authors: Ernest Nadal Delvys Rodr íguez-Abreu Marta Sim ó Bartomeu Massut í Oscar Juan Gerardo Huidobro Rafael L ópez Javier De Castro Anna Estival Joaqu ín Mosquera Ivana Sullivan Enriqueta Felip Ana Blasco Maria Guirado Eva Pereira Noelia Vilari ño Valent Source Type: research
Enhanced immune responses in dexamethasone immunosuppressed male rats supplemented with herbal extracts, chitosan nanoparticles, and their conjugates
Int J Biol Macromol. 2023 Aug 11:126170. doi: 10.1016/j.ijbiomac.2023.126170. Online ahead of print.ABSTRACTNowadays, the world is challenged with highly contagious diseases, one of their preliminary virulence mechanisms is the suppression of innate immunity. Therefore, promoting natural immunity is a good precautionary strategy. we investigated and compared the effects of several natural herbal extracts -Moringa oleifera, Ziziphus spina christi, and Saussurea costus, and chitosan nanoparticles (CS NPs)- as well as conjugated extracts with CS NPs on the immunological parameters of dexamethasone immunosuppressed (IS) male r...
Source: Cancer Control - August 13, 2023 Category: Cancer & Oncology Authors: Selvia S Milad Sara E Ali Mahmoud Z Attia Marwa S Khattab Eman S El-Ashaal Hisham A Elshoky Afaf M Azouz Source Type: research
Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy
CONCLUSIONS: TC showed superiority in early and delayed CINV control in carboplatin AUC ≥ 4 regimens, with no significant differences among cancer types. Change in NEPA administration timing has beneficial implications; it allows NEPA to be administered at hospitals before chemotherapy session.PMID:37563932 | DOI:10.1177/10781552231194077
Source: Cancer Control - August 11, 2023 Category: Cancer & Oncology Authors: Marta Albanell-Fern ández Ángela Pérez Sánchez In és Monge-Escartín Gisela Riu-Viladoms M ª Carmen Rodríguez Mues M ª Lourdes Corominas Bosch Lydia Gaba Garc ía Neus Bast é Rollán Noem í Reguart Dolors Soy Muner Esther Carcelero San Mart ín Source Type: research
Olanzapine as an add-on, pre-operative anti-emetic drug for postoperative nausea or vomiting: a randomised controlled trial
This study aimed to examine whether pre-operative olanzapine, as a prophylactic anti-emetic added to intra-operative dexamethasone, ondansetron and total intravenous anaesthesia, reduced the incidence of postoperative nausea or vomiting. We performed a multiply-blinded randomised controlled trial in patients aged 18-60 years with cancer at high risk of postoperative nausea or vomiting (three or four risk factors according to the Apfel criteria) plus a previous history of chemotherapy-induced nausea and vomiting. Patients were allocated at random to receive 10 mg olanzapine or placebo orally 1 h before surgery in addition t...
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: T R Grigio H Timmerman J V B Martins A Slullitel A P Wolff A M Sousa Source Type: research
IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
Haematologica. 2023 Jul 13. doi: 10.3324/haematol.2022.282538. Online ahead of print.ABSTRACTMultiple Myeloma (MM) is a plasma-cell neoplasm originating in the bone marrow and is the second most common blood cancer in the United States. One challenge in understanding the pathogenesis of MM and improving treatment is a lack of immunocompetent mouse models. We previously developed the IL6Myc mouse that generates plasmacytomas at 100% penetrance that phenotypically resemble aggressive MM. Using comprehensive genomic analysis, we found that the IL6Myc tumors resemble aggressive MM by RNA and protein expression. We also found t...
Source: Haematologica - July 13, 2023 Category: Hematology Authors: Michael D Pisano Fumou Sun Yan Cheng Deepak Parashar Vivian Zhou Xuefang Jing Ramakrishna Sompallae Jenica Abrudan Michael T Zimmermann Angela Mathison Siegfried Janz Miles A Pufall Source Type: research
